Progress of disease transformation and drug discontinuation in chronic myeloid leukemia / 白血病·淋巴瘤

ABSTRACT

Since the identification of BCR-ABL fusion gene and the advent of targeted tyrosine kinase inhibitors (TKI), patients with chronic myeloid leukemia (CML) have been "walking" on the path of chronic disease for around twenty years. In recent years, the second - and third -generation TKI have provided further protection for the long-term survival of CML patients. However, TKI discontinuation and the prognostic situation of a small number of patients with TKI resistance or carrying poor prognostic genes are still hot issues in CML-related researches. This article reviews the research progress of CML at the 62nd American Society of Hematology Annual Meeting.